Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYCLONE 3: Abemaciclib + Abiraterone + Prednisone in High-Risk Metastatic Hormone-Sensitive Prostate Cancer
NCT05288166Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 24
01
Overview
A Phase 3 trial of abemaciclib in prostate cancer (PCa), sponsored by Eli Lilly and Company. Started Apr 2022; status: active, not recruiting.
02
Drugs
abemaciclib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05288166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05288166.